Effect of FLAG program on relapsed or refractory acute myeloid leukemia cases

Objective: To study the effect of FLAG program on relapsed or refractory acute myeloid leukemia.Methods:A total of 37 patients with relapsed or refractory acute myeloid leukemia were treated with FLAG program: fludarabine 30 mg/m2,dl-d5,Ara-C 2 g,d1-d5,granulocyte colony stimulating factor(G-CSF) 5 μg/kg d0 until the white blood cell recovery above 1.5 × 109 / L.Results: 12 cases had complete remission(CR),CR rate was 32.4%.The median overall survival(OS) was 6.2 months,median progress free survival(PFS) was 10.3 months.There was significant difference between recurrence patients with pre-FLAG treatment of less than 3 cycles of chemotherapy and patients with three or more cycles of chemotherapy(P0.01) in 26 cases.Conclusions: FLAG program is a better choice for relapse or refractory patients with acute myelogenous leukemia.